Leeds Innovation Centre
103 Clarendon Road
Tissue Regenix Ltd.
Tissue Regenix is developing what it describes as "de-cellularized biological scaffolds," which are meant to function like native tissue. Tissue Regenix uses tissue taken from pigs or cows as its starting material, then carefully strips out cells, leaving behind a complex matrix of proteins such as collagen and elastin. Once this matrix is implanted, the body's own cells go into it and encourage cell recruitment and tissue formation.
More from R&D
• By
Otsuka bested Vera on Phase III immunoglobulin A nephropathy data for proteinuria, but analysts wonder if the difference is especially meaningful.
• By
The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.
• By
The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.
• By
Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.
More from Scrip
Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.
• By
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.
• By
IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?